Vandortuzumab, a novel protein, shows an intriguing therapeutic agent targeting CD40, a key receptor involved in immune activity. Its mechanism with action involves blocking CD40 signaling, seemingly leading to reduced https://www.targetmol.com/compound/vandortuzumab